← All trials
NCT04430790
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2020
- Primary completion
- May 1, 2024
- Completion date
- May 1, 2030
- First posted
- Jun 12, 2020
- Last posted
- Jun 12, 2020
- Enrollment
- 398
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Erasmus University RotterdamLead sponsor
- University of AmsterdamCollaborator
- Katholieke Universiteit LeuvenCollaborator
- Erasmus University RotterdamReponsible party - principal investigator
- Nederlands Neonataal Netwerk (N3), the NetherlandsCollaborator
- Katholieke Universiteit LeuvenOverall official - principal investigator
- Katholieke Universiteit LeuvenStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.